16 results
424B3
PROK
ProKidney Corp.
21 Apr 23
Prospectus supplement
4:18pm
principal competitors include developers of SGLT2 inhibitors and Mineral Receptor Agonists (“MRAs”), which are small-molecule therapies recently … related to bone and mineral metabolism and hematopoiesis. Observations supporting this include trends toward decreasing phosphorus and increasing
POS AM
PROK
ProKidney Corp.
17 Apr 23
Prospectus update (post-effective amendment)
5:01pm
for kidney diseases are ongoing in Japan. We believe that our principal competitors include developers of SGLT2 inhibitors and Mineral Receptor … that injected SRCs may augment other important kidney functions related to bone and mineral metabolism and hematopoiesis. Observations supporting
424B3
PROK
ProKidney Corp.
9 Sep 22
Prospectus supplement
5:05pm
developers of SGLT2 inhibitors and Mineral Receptor Agonists (“MRAs”), which are small-molecule therapies recently approved to lower risks of CKD
DEFM14A
9e81ifgx64dydiv
10 Jun 22
Proxy related to merger
4:54pm
DEFA14A
q1fbv
28 Apr 22
Additional proxy soliciting materials
8:02am
DEFA14A
EX-99.1
3d3jjr9y
28 Apr 22
Additional proxy soliciting materials
8:02am
8-K
EX-99.1
ls330 ik6zbdmb
28 Apr 22
Regulation FD Disclosure
7:57am
PRER14A
k7xzc 5rrf
11 Apr 22
Preliminary revised proxy
5:29pm
PREM14A
7px5mdwhnppp ul6hsdv
14 Feb 22
Preliminary proxy related to merger
4:55pm
DEFA14A
tpa0yp7ir 3d
18 Jan 22
Additional proxy soliciting materials
5:15pm
DEFA14A
josr64xr dm5bv
18 Jan 22
Additional proxy soliciting materials
7:14am
8-K
EX-99.2
v540u mf1g
18 Jan 22
Entry into a Material Definitive Agreement
7:05am
- Prev
- 1
- Next